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Abstract: Sweeteners that are a hundred thousand times sweeter than sucrose are being consumed as
sugar substitutes. The effects of sweeteners on gut microbiota composition have not been completely
elucidated yet, and numerous gaps related to the effects of nonnutritive sweeteners (NNS) on health still
remain. The NNS aspartame and acesulfame-K do not interact with the colonic microbiota, and, as a
result, potentially expected shifts in the gut microbiota are relatively limited, although acesulfame-K
intake increases Firmicutes and depletes Akkermansia muciniphila populations. On the other hand,
saccharin and sucralose provoke changes in the gut microbiota populations, while no health effects,
either positive or negative, have been described; hence, further studies are needed to clarify these
observations. Steviol glycosides might directly interact with the intestinal microbiota and need bacteria
for their metabolization, thus they could potentially alter the bacterial population. Finally, the effects of
polyols, which are sugar alcohols that can reach the colonic microbiota, are not completely understood;
polyols have some prebiotics properties, with laxative effects, especially in patients with inflammatory
bowel syndrome. In this review, we aimed to update the current evidence about sweeteners’ effects
on and their plausible biological interactions with the gut microbiota.
Keywords: nonnutritive sweeteners; sweetening agents; gut microbiota
1. Introduction
Excessive sugar consumption has become an important public health concern due to its adverse
effects on health and metabolic consequences such as obesity, insulin resistance, metabolic syndrome,
cardiovascular diseases, and type 2 diabetes. One century ago, sweetening agents or sweeteners—sugar
substitutes that mimic the sweet taste—emerged as an alternative to sucrose and glucose–fructose
syrups consumption to reduce energy intake [1,2]. However, the impact of sugar consumption on health
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continues to be a controversial topic in relation to its effects on metabolic disease [3]. Some contradictory
results were published in 2015 about sweeteners and gut microbiota. Suez et al. concluded that some
sweeteners may affect the human microbiome, and consequently more studies are needed [4]. In contrast,
Frankelfeld et al. [5] reported no differences in median bacterial abundance across consumers and
non-consumers of sweeteners.
Sweeteners are between several hundred to thousands of times sweeter than sucrose and they
do not contain too many calories. They include nonnutritive sweeteners (NNS), which have a higher
sweetening intensity than other sweeteners, such as acesulfame K (ace-K), advantame, aspartame,
aspartame–acesulfame salt, cyclamate, neohesperidin dihydrochalcone, neotame, saccharin, steviol
glycosides (including 10 different glycosides), sucralose, and thaumatin, low-calorie sweeteners (LCS),
such as polyols or sugar alcohols and other new sugars which are low-digestible carbohydrates derived
from the hydrogenation of their sugar or syrup sources. Polyols are around 25%–100% as sweet as
sugar and include erythritol, hydrogenated starch hydrolysates (sometimes listed as maltitol syrup,
hydrogenated glucose syrup, polyglycitol, polyglucitol, or simply HSH), isomalt, lactitol, maltitol,
mannitol, sorbitol, and xylitol. All of them are considered safe for human consumption as long as
they are consumed within the acceptable daily intake [6]. This safety was claimed by the European
Food Safety Authority (EFSA) except for cyclamate, which is not approved by the US Food and
Drug Administration [1,7,8].
In 2019, we reviewed the effects of sweeteners on the gut microbiota, considering both experimental
studies and clinical trials, and we reported that, among NNS, only saccharin and sucralose shift the
populations of the gut microbiota, although more human studies are needed to clarify those observations.
Within nutritive sweeteners (NS), only stevia extracts seem to affect gut microbiota composition,
while some polyols, such as isomalt and maltitol which can reach the colon, increase Bifidobacterium
in healthy subjects and might act as prebiotics. Besides, lactitol can decrease Bacteroides, Clostridium,
coliforms, and Eubacterium, increasing butyrate and IgA secretion in humans [1]. Thus, we concluded
that still more studies are needed; however, as the plausible biological interaction between sweeteners
and intestinal microbiota has not been reported elsewhere, we aimed to review and update the current
knowledge about sweeteners and gut microbiota interactions in humans.
A comprehensive literature search was conducted in PubMed, Embase®, and Scopus using different
combinations of the following keywords: aspartame, acesulfame-K, cyclamate, sucralose, saccharin,
steviol glycosides, erythritol, isomalt, lactitol, maltitol, sorbitol, mannitol, xylitol, and microbiota,
with special attention and interest to what was published from February 2018 to March 2020.
2. Biological Plausibility: Which Low- and Non-Calorie Sweetener (LNCS) Could Potentially
Affect the Colonic Microbiota?
Biological plausibility is one component of a method of reasoning that can establish a
cause-and-effect relationship between a biological factor and a particular disease or adverse effect
based on assessing the strength of evidence, since the work of Bradford Hill [9]. Here, we will assess
biological plausibility between different sweeteners and gut microbiota composition. Although we
usually refer to the different low- and non-calorie sweeteners (LNCS) as if they were a single molecule,
it is well known that they do not share their absorption, distribution, metabolism, and excretion
(ADME) profiles. Therefore, the extrapolation of the effect of a particular LNCS on the intestinal
microbiota to all LNCS is unappropriated. These differences are crucial to understanding if each LNCS
has the potential to alter the intestinal microbiota, directly or indirectly. For more detailed information
on the metabolic fate of each LNCS beyond its relationship with the colonic microbiota, the excellent
review by Magnuson et al. (2016) [10] can be consulted.
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2.1. Effects of Non-Nutritive Low-Calorie Sweeteners on the Gut Microbiota
2.1.1. Aspartame
Aspartame is a methyl ester of a dipeptide composed of L-phenylalanine and aspartic acid.
When ingested, this dipeptide undergoes enzymatic hydrolysis in the gastrointestinal lumen and in
the cells of the internal intestinal mucosa (by peptidases and intestinal esterases), so that virtually no
aspartame enters the general circulation [11,12]. Hence, aspartame as an intact molecule cannot interact
directly with the colonic microbiota. The three digestion products (aspartic acid, L-phenylalanine,
and methanol) are rapidly absorbed in the duodenum and jejunum [12], reaching the systemic
circulation without passing through the colon [10]. These degradation products are presented in
the same way as when they are absorbed from vegetables, fruits, dairy, or meat, and at much lower
concentrations than when they are derived from such foods [11]. These products follow their usual
metabolic pathways.
Methanol enters the portal circulation into the liver and, by the enzymatic action of alcohol
dehydrogenase, is metabolized to formaldehyde, which in turn, by the action of formaldehyde
dehydrogenase, is oxidized to formic acid. Formic acid can be eliminated by the respiratory tract
as carbon dioxide or excreted into the urine [10,11]. Aspartate undergoes a transamination reaction
in the enterocytes, becoming oxalacetate. Oxalacetate and aspartate are interconverted in the body
and can participate in the urea cycle and gluconeogenesis in the liver. Excess aspartate is eliminated
in the urine [10]. Phenylalanine is absorbed in the gastrointestinal tract mucosa. It enters the liver
through portal circulation, where, by the action of phenylalanine hydroxylase, can be converted
into tyrosine. Phenylalanine that reaches the systemic circulation can be distributed throughout the
body [11]. Its excess is excreted in the urine [13].
Based on the abovementioned information, the finding of a positive association between intake of
aspartame and alteration of the colonic microbiota of rodents could be in fact due to the effect of what
the animals stop eating rather than to the effect of aspartame intake itself. This last concept applies to all
LNCS. However, a recent study carried out in female Sprague Dawley rats subjected to a high-fat/sucrose
(HFSD), a HFSD + aspartame (5–7 mg kg−1 day−1), or a HFSD + stevia (2–3 mg kg−1 day−1) diet showed
an increase of body fat in the offspring at weaning following maternal consumption of aspartame
and stevia in the HSFD. In addition, glucose tolerance was altered, particularly with aspartame.
Akkermansia muciniphila and Enterobacteriaceae concentrations were higher in mothers compared with
their offspring. Regarding the cecal microbiota, a reduced abundance of Enterococcaceae, Enterococcus,
and Parasutterella and an increased abundance of Clostridium cluster IV were found in the aspartame
group. Moreover, fecal transplantation from offspring to germ-free mice produced an altered gut
microbiota, causing impaired adiposity and glucose tolerance. In addition, increased concentrations of
Porphyromonadaceae in males and females obese–aspartame and obese–stevia offspring were found [14].
In contrast, in the study by Suez et al., food intake in mice assigned to a water group with LNCS
(aspartame, sucralose, and saccharin) was reduced by up to 50%. It is known that dietary factors are
key determinants of the composition of the intestinal microbiota; indeed, differences in both total
caloric intake and the type of food consumed can lead to a different microbial composition [15–17].
Thus, the intestinal microbiota might have been altered by a reduced consumption of fiber, protein,
fat, and carbohydrates; therefore, it seems uncertain that the reported change in the intestinal microbiota
was caused by the LNCS, and the changes that diet per se may provoke in the intestine should be considered.
Nonetheless, there are studies that reveal possible modifications of the microbiota due to the use of
aspartame. The study by Mahmud et al. analyzes the combined and individual effects of the administration
of low concentrations of aspartame and Ace-K. Induction of Escherichia coli growth and expression of
some important genes which may be related to its colonization in the gut were observed [18]. In another
study with human fecal samples, aspartame administration significantly increased Bifidobacterium and
Blautia coccoides growth and decreased the Bacteroides/Prevotella ratio; nevertheless, the aspartame-based
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sweetener used in this study was rich in maltodextrin, thus, the authors did not study the effect of
aspartame alone [19].
2.1.2. Potassium Acesulfame (Ace-K)
After its intake, Ace-K is absorbed almost completely in the small intestine as an intact molecule
and distributed by the blood to different tissues. Without undergoing any metabolization, more than
99% of Ace-K is excreted in the urinary tract within the first 24 h, with less than 1% being eliminated
in the feces [10,20]. The minimum amount of Ace-K ingested, its rapid absorption, and its urinary
excretion causes the Ace-K concentration that reaches the fecal or colonic bacteria to be negligible [10,21].
Therefore, it is extremely unlikely that this LNCS could have a direct effect on the colonic microbiota [16].
However, some studies have reported small shifts in the gut microbiota composition following
Ace-K intake.
A cross-sectional study was conducted in humans and showed no modifications in the intestinal
microbiota nor significant differences by sex, contrary to the study conducted in rats by Bian X et al. [22].
Other studies also indicate that Ace-K causes changes in the microbiota and their metabolites, such as
butyrate and pyruvate [22,23]. The study carried out by Uebanso et al. suggests that the daily intake
of maximum adequate diary intake (ADI) levels of Ace-K does not affect the relative amount of
the Clostridium cluster XIVa in the fecal microbiome [24]. In contrast, a study in mice that received
150 mg kg−1 of Ace-K by free drinking during 8 weeks, showed that lymphocyte recruitment was
increased, with augmented expression of inflammatory cytokines and adhesion molecules [25].
Recent studies in rats indicate that administration of a mixture of sucralose and Ace-K at concentrations
near the upper limit of ADI for human consumption during mice pregnancy has consequences on the
progeny, causing metabolic and microbiome alterations. The authors observed an increase in Firmicutes
and a depletion of A. muciniphila, which is a beneficial bacterium inversely correlated with fat mass
gain, type 1 diabetes, and inflammatory bowel syndrome (IBS) [26]. The researchers also indicated an
increase in the variety of species in the microbiota; however, A. muciniphila was significantly depleted,
suggesting that the divergence between mothers’ and pups’ microbiomes was due to increasing
NNS concentrations [27].
Regarding the bacteriostatic effect of Ace-K, this sweetener shows a strong inhibitory effect on the
growth of E. coli HB101 and E. coli K-12 [28]. In contrast, using a concentration of Ace-K of 2.5 mg/mL,
the result was an induction in E. coli growth, whereas the growth stimulation decreased gradually
when higher concentrations of sweetener were used [18].
2.1.3. Cyclamate
Cyclamate is the sodium or calcium salt of cyclamic acid (cyclohexanesulfamic acid), which itself
is prepared by the sulfonation of cyclohexylamine and is eliminated in the feces [29]. In a study carried
out by Vamanu et al. [30], the authors determined the effect of sweeteners on the microbiota pattern
using an in vitro model. In this study, the total quantity of synthesized short-chain fatty acids (SCFA)
and the number of microorganisms were decreased, and a negative influence on the fermentative profile
was observed, although with an increase of Bifidobacterium. The ratio of butyric/propionic acids was
also affected, indicating that those SCFA could affect the gut microbiota composition. Cyclamate also
exerts a positive effect, producing an inhibitory anaerobic fermentation of glucose in a rat model of
intestinal gut microbiota [28].
Cyclamate and sucralose can alter the ratio between butyric and propionic acids [30]. SCFA have
multiple effects on human health. Butyric acid has anti-obesogenic effects, reduces insulin resistance,
and improves dyslipidemia [31]. Lower concentrations of propionic and butyric acids have been
positively correlated with the four subtypes of IBS and can be harmful to people with that disease [32].
Overall, it seems that cyclamate has some effects on gut microbiota composition, but more studies on
its possible effect on human health are needed.
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2.1.4. Sucralose
Sucralose has a very low level of absorption (less than 15%) and it is practically not metabolized.
Therefore, after intake, more than 85% of sucralose reaches the colon unchanged [10]. The small
proportion of sucralose that is absorbed is eliminated in the urine mainly unchanged, though two
glucuronides of sucralose were also detected in a small proportion (approximately 2%) [33].
Although more than 85% of the ingested sucralose contacts the colonic microbiota, between 94%
and 99% of this LNCS is recovered in the feces without any structural change, thus indicating little
or no metabolism by the gut microbiota [10]. Thus, sucralose does not appear to be a substrate for
the colonic microbiota [16]. Nevertheless, considering the practically null microbial metabolism of
sucralose, we must be cautious when interpreting the results of studies that indicate an alteration of
the intestinal microbiota after sucralose consumption [17]. In those cases, it will be worth investigating
whether pure sucralose or a commercial formulation was used in the research, since these formulations
usually contain around 1% of sucralose and 99% of the carriers maltodextrins [16].
On the other hand, it has been shown that sucralose promotes inflammation in a mouse
model of human Crohn’s disease-like ileitis as well as dysbiosis of the gut microbiota [34].
Furthermore, sucralose causes a decrease in the number of Firmicutes species [35]. This result is the
opposite to that reporter by Olivier-Van Stichelen et al., who found that Firmicutes doubled, including
the Clostridiales families Lachnospiraceae and Ruminococcaceae (e.g., Oscillospira), in mice’s pups [27].
Wang et al. observed an increase of Firmicutes and a tendency to decrease for Bacteroidetes [28].
These authors did not observe changes in Actinobacteria and Proteobacteria phyla in mice fed with
a chow diet, but they reported a synergistic effect when sucralose was provided in the context of a
high-fat diet. On the other hand, a chow diet might cause a significant increase in Bifidobacterium [28].
A study carried out in humans examined the short-term effect of sucralose consumption on glucose
homeostasis and gut microbiome in healthy male volunteers. The authors concluded that no changes
occurred in the gut microbiome due to sucralose intake [36]. In contrast, another study shows an
increase in the abundance of pro-inflammatory bacteria like Turicibacter, which was associated with
hepatic inflammation, after sucralose administration [37].
Splenda administration in mice was associated with a high presence of Bacteroidetes, an enhanced
overgrowth of E. coli, and the expansion of Proteobacteria [38]. The effect of sucralose was analyzed
in fecal samples from 13 healthy volunteers. The authors found increased abundances of Escherichia,
Shigella, and Bilophila. With regard to SCFA, increased production of valeric acid was observed [19].
A recent publication evaluated the short-term effect of sucralose consumption on glycemic control
and its interaction with the intestinal microbiota (comparison before/after the intervention by 16S rRNA
sequencing) in healthy subjects. This study concluded that consumption of high doses of sucralose
(75% of the ADI) for 7 days did not alter glycemic control, insulin resistance, or intestinal microbiome
at the phylum level [36].
Although previous human studies showed similar results concerning glycemic control
(glycosylated hemoglobin, fasting blood glucose, C-peptide), both in diabetic [39] and in non-diabetic
populations [40], this is the first time that a randomized, controlled, double-blind study concomitantly
evaluated the composition of the intestinal microbiome in healthy subjects, thus providing a better
level of evidence in comparison to other earlier published trials.
2.1.5. Saccharin
After intake, more than 85% of saccharin is absorbed as an intact molecule, since it does not undergo
gastrointestinal metabolism. Once absorbed, it binds to plasma proteins and is distributed throughout
the body. Finally, it is eliminated by urine through active tubular transport [10,41,42]. The small
percentage of non-absorbed saccharin is excreted into the feces, indicating that high concentrations
of this LNCS could lead to changes in the composition of the intestinal microbial population [16].
It is important to highlight that one of the main studies that reported an alteration of the intestinal
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microbiota with the consumption of saccharin [17] was carried out by administering the full ADI of
saccharin, which does not correspond to what happens with habitual human consumption.
In an in vitro model study, saccharin produced an increase in Bifidobacterium. Not only saccharin
but also sucralose caused a decrease in the number of Firmicutes species, directly correlated with the
SCFA level [30].
Some herbicides, which are considered nowadays safe, can change the gut microbiota of animals
in the early stages of embryonic development. Indeed, exposure to glyphosate and glyphosate in
combination with saccharin contributes to the broader reproduction of pathogenic bacteria such as
Klebsiella, Citrobacter, Enterobacter, and Pseudomonas [43]. On the other hand, studies show that saccharin
administration can also disrupt monolayer integrity and alter paracellular permeability in a Caco-2 cell
monolayer model [44].
Overall, saccharin administration also promotes Bacteroidetes, Turicibacter, and Clostridiales and
reduces Firmicutes abundances. The Turicibacter bacteria increases have been related to a pro-inflammatory
effect of saccharin [37].
The effect of a mixture of fiber–prebiotics and saccharin–eugenol has been evaluated in dogs.
Four diets were prepared: control diet, containing 5% of cellulose; diet containing a 5% fiber and
prebiotic blend; diet containing 0.02% of saccharin (sweetener SUCRAM) and eugenol and 5% of a
fiber and prebiotic blend plus 0.02% of saccharin and eugenol. The use of saccharine did not affect
species richness measured by alpha-diversity or alter the proportions of bacterial phyla. No changes
were observed in fecal microbial communities [45]. More studies are needed to confirm these saccharin
effects using different concentrations and animal models.
2.1.6. Steviol Glycosides
Steviol glycosides can be extracted from the leaves of Stevia rebaudiana. They all have a central
steviol structure, conjugated with different sugar residues, such as stevioside and rebaudioside A,
which all are steviol glycosides. Steviol glycosides are hydrolyzed neither by enzymes nor by the acid
present in the upper gastrointestinal tract [46]. Therefore, they pass through the upper portion of the
gastrointestinal tract without being absorbed and enter the colon as intact molecules [47]. In the colon,
bacteria of the Bacteroidacea family eliminate the sugar residues that are conjugated to steviol [47,48].
While these sugar residues may represent a source of energy for the microbiota [49], it is worth noting
that the energy contribution is negligible, given the low total daily intake of steviol glycosides [50].
The resulting steviol is not a substrate for the intestinal microbiota, since it is resistant to bacterial
degradation [48]. Hence, steviol is completely absorbed and reaches the liver where it is conjugated
with glucuronic acid. Steviol glucuronide is mainly excreted in the urine in humans [51,52].
While steviol glycosides interact with the colonic microbiota, there are no reports indicating that
these compounds could affect bacteria negatively [30]. A recent study showed that steviol incubation
in the GIS1–phase 2 system, an in vitro system that simulates the human intestinal microbial ecosystem,
reduced the ammonium level and Bifidobacterium and exerted a negative influence on the fermentative
profile, resulting in higher pH and SCFA ratio [30].
S. rebaudiana is another natural steviol glycoside 250 times sweeter than sucrose [53]. In Europe,
only the purified steviol glycosides are approved for use in food, and the ADI of 4 mg kg−1 of body
weight per day is safe (EU Regulation (EU) 1129/2011) [1,7,54]. Another study recently reported that a
low dose of stevia rebaudioside A alters gut microbiota composition and reduces nucleus accumbens
tyrosine hydroxylase and dopamine transporter mRNA levels in rebaudioside A-supplemented rats.
Nonetheless, the oligofructose-enriched inulin prebiotic, in the presence or absence of rebaudioside A,
reduced fat mass, food intake, gut permeability, and cecal SCFA concentration. However, only stevia
rebaudioside A increased SCFAs acetate and valerate, which are positively correlated with fat mass and
total weight. Hence, stevia rebaudioside A seems to decrease the “healthy” status of the gut microbiota [55].
Chronic stevia consumption has effects on gut microbiota and immunity in the small intestine of
young mice. In 21-day-old mice treated with sucrose, Splenda, and stevia, mice preferred the consumption
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of Splenda and stevia. Besides, those mice showed an increase in CD3+ lymphocytes in Peyer’s patches,
but only stevia induced an increase in the lamina propria. Both Splenda and stevia elevated leptin,
C-peptide, IL-6, and IL-17 and decreased resistin. Stevia modified the predominantly genera Bacillus
such as Bacillus aerius, Bacillus circulans, Bacillus licheniformis, and Bacillus safensis, although the authors
observed effects on Streptococcus saliviloxodontae, Oceanobacillus sojae, and Staphylococcus lugdunensis.
Even though the results of this study are significant, they have some limitations. The modifications
observed in the immune system of the mucous membranes and in the microbiota of the small intestine in
young mice after weaning depend on age and diet. This study used culture media and not metagenomic
approaches, and some results might be related to some carriers present in the evaluated products,
such as maltodextrins [56].
Recently, by testing stevia glycosides and erythritol, which are often combined in food preparation
to minimize changes in the organoleptic profile, in an in vivo Cebus apella model, changes in bacteria
growth and gut microbial structure and diversity have been observed [57]. Overall, stevia seems to
modify the gut microbiota; however, further studies are needed to clarify its specific effects.
Although different changes in the intestinal microbiota have been described in relation to the
influence of sweeteners on the immune system, the wide use of aspartame, ace-K, cyclamate, sucralose,
saccharin and steviol glycosides makes it necessary to carry out other analyses to complete the picture
of the influence that these sweeteners have on the intestinal microbiota.
2.2. Effects of Nutritive Low-Calorie Sweeteners on the Gut Microbiota
2.2.1. Polyols
Polyols are a group of compounds used in an increasingly wide variety of commercial foods as
additives. They are quite stable at high temperatures and various pH and do not interfere in Maillard
reactions, conferring organoleptic characteristics to the foods. Polyols are naturally present in fruits,
vegetables, and mushrooms and are used to produce food without added sugar, reducing the sugar
content in recipes. In addition, polyols are non-cariogenic, do not induce salivation, and do not
interfere with insulin and glucose levels in the blood. Nevertheless, the excessive consumption of
polyols causes gastrointestinal symptoms and laxative effects, which can be even worse in patients with
IBS. As we described previously, the FDA, the Codex Alimentarius, and the EFSA have approved eight
different polyols, i.e., erythritol, hydrogenated starch hydrolysates, isomalt, lactitol, maltitol, mannitol,
sorbitol, and xylitol, for use as bulk sweeteners in human foods [1,58]. Indeed, in September 2019,
EFSA launched an open consultation on the “Protocol for the assessment of hazard identification and
characterization of the sweeteners”, which will be used for the evaluation of the safety of sweeteners
under the re-evaluation program of food additives. The evaluation should be completed by the end
of 2020 [59].
2.2.2. Erythritol
Erythritol (E-968) is a four-carbon sugar alcohol that has a fast absorption through the small
intestine with a very low metabolization and it is over 90% excreted unchanged in the urine [58].
Furthermore, an unabsorbed part (~10%) is fermented in the large intestine by the colonic microbiota,
which consequently rarely leads to gas production [60]. Hence, the limited amount of erythritol that
reaches the colon could be the explanation of the lack of evidence of effects of erythritol on the gut
microbiota in humans, based on clinical trials as we previously reported [1]. Nevertheless, a recent
in vitro study demonstrated that low doses of erythritol (25 µg mL−1, 50 µg mL−1, and 100 µg mL−1)
did not exert any effect on the growth of Escherichia, Enterococcus, Lactobacillus, Ruminococcus and
Bacteroides in the human gut microbiota. Moreover, erythritol doses did not disrupt alpha and beta
diversities or the composition of the human gut microbial community [57]. In contrast, butyric and
pentanoic acids were increased significantly after erythritol consumption, indicating that this polyol
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may be able to affect the function of the human gut microbiota. Indeed, the authors reported that this
change in SCFAs production was due to the 10% of erythritol that reaches the human colon [57].
2.2.3. Isomalt
Hydrogenated isomalt, isomaltitol (E-953), is not absorbed by the small intestine and is easily fermented
in the colon by the microbiota [61]. This fermented fraction of ingested isomalt is approximately 90% [62].
Therefore, it is expected that isomalt is capable of altering the bacterial population. Isomalt has been proposed
as a prebiotic carbohydrate that might contribute to a healthy luminal colonic mucosal environment,
with bifidogenic properties and high butyrate production [63]. Accordingly, besides evidence reported
in Ruiz-Ojeda et al., 2019 [1], a recent study based on the administration of buckwheat honey
to human gut microbes cultures reported that the principal constituents of buckwheat honey are
oligosaccharides with a low degree of polymerization, including isomalt and isomaltotriose, which may
serve as food to promote the growth of indigenous intestinal probiotics such as Bifidobacterium [64].
In addition, an increase in the abundance of Escherichia/Shigella and Streptococcus was also reported,
while the alpha diversity, as well as the abundance of Prevotella, Faecalibacterium, and Lachnospiraceae
incertae sedis, were decreased, thus fostering a reduction of pathogenic bacteria in the gut tract [64].
However, this might be also explained by the polyphenols composition of the buckwheat honey studied,
since polyphenols also markedly affect the gut microbiota [64]. Indeed, the authors concluded that
phenolic compounds and oligosaccharides in buckwheat honey appear to synergistically impact human
intestinal microbes to enhance the growth of probiotics. More efforts, especially in vivo, are required
to elucidate the possible specific impact of isomalt on the gut microbiota.
2.2.4. Lactitol
Lactitol (E-966) is a disaccharide normally not absorbed in the small intestine [65] that therefore
reaches the lower gut where it is fermented, producing both gases and SCFA [66]. Lactitol mitigates
pathogenic translocation in the small intestine by the reduction of permeability and stimulates the
growth of bifidobacteria and lactobacilli [67]. Thus, similarly to isomalt, lactitol could act as a prebiotic,
enhancing the composition of the intestinal microbiota, even when consumed at low doses as a
sweetener, normally 10 grams [68]. Nevertheless, it is important to highlight that lactitol, due to its
limited sweetening power, is usually used in combination with other intense sweeteners [69] or a set
of prebiotics [70], and this could disturb the results concerning its effect on the intestinal microbiota.
Furthermore, it has also been studied as a synbiotic product along with Lactobacillus acidophilus
NCFM and jointly promoted beneficial changes since it led to a decrease in the abundance of the
Blautia coccoides–Eubacterium rectale bacterial group and Clostridium cluster XIVab counts in the elderly
population [71]. Since 2018, two studies were identified regarding lactitol and the gut microbiota.
One trial was based on the administration of probiotics, synbiotics, probiotics together with lactitol,
or only lactitol to mice with acute colitis. The authors found that the lactitol group showed higher
levels of Akkermansia compared with the control, probiotic (Bifidobacterium and Lactobacillus), and synbiotic
(probiotics and inulin) groups. It is worth highlighting this work, since Akkermansia seems to ameliorate
the inflammatory response and insulin resistance in obese and diabetic patients [72], protecting the
intestinal epithelial cells and enhancing the mucosal barrier function [73]. As the genome of Akkermansia
was proved to be able to encode a wide variety of secretory proteins such as glycohydrolyzases [74],
the authors speculated that Akkermansia might be able to decompose lactitol and promote its own
proliferation [75]. Furthermore, the supplementation of probiotics and prebiotics, including lactitol,
induced an increment of the proportion of helpful bacteria and regulated the balance of the intestinal
microbiota [75]. For instance, the abundance of Bifidobacterium was increased in all the experimental
groups in comparison with the control. However, the observed effect might not be exerted by lactitol
itself [75]. Another study was performed in Korean adults to evaluate the efficacy of supplementation
with the prebiotic UG1601 (based on inulin (61.5%), lactitol (34.6%), and an aloe vera gel (3.9%))
for 4 weeks to alleviate the symptoms of constipation associated with the gut microbiota [70].
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Here, the clinical trial showed that the prebiotic UG1601 in patients with mild constipation resulted in
decreased serum concentrations of the bacterial endotoxin lipopolysaccharide and its receptor CD 14.
Additionally, it increased the abundance of Roseburia hominis, a major butyrate producer, which could
be related to the observed reduction of the levels of these endotoxemia markers [70]. In summary,
lactitol along with other compounds, may induce changes in the gut microbiota, but further studies are
needed to demonstrate whether lactitol itself triggers an effect on the gut microbiota.
2.2.5. Maltitol
Maltitol (E-965) is obtained through the hydrolysis, reduction, and hydrogenation of starch.
This polyol has a very slow absorption rate, being fermented in the colon. Thus, as we previously
mentioned, it is expected that maltitol is susceptible fermentation by the gut microbiota [1]. To date,
only one clinical trial has been reported which studied the effect of maltitol present in experimental
chocolate on the gut microbiota. The authors concluded that both maltitol and polydextrose, as well as
maltitol alone, increased the amount of fecal bifidobacteria, lactobacilli, and SCFA compared with the
control chocolate [26]. Besides evidence reported by Ruiz-Ojeda et al., 2019 [1], there are no additional
studies. Although maltitol could be a good alternative with high sweetening capacity (~90%), safe,
and non-cariogenic, data to determine the specific effects of maltitol on the gut microbiota are not
still sufficient.
2.2.6. Sorbitol
Sorbitol or D-glucitol (E-420) is partially absorbed in the upper gastrointestinal tract, where it
undergoes digestion, while the non-absorbed portion is extensively fermented to SCFA and gases by the
colonic microbiota [62]. Consumers can suffer slight gastrointestinal symptoms, such as flatulence or
bloating, or more severe symptoms when it is ingested at high doses as 20 g d−1 [76]. Overall, studies on
this isomeric polyol and its effect on the gastrointestinal tract are mostly focused on the symptomatology
induced by sorbitol than on its possible capacity to alter the gut microbiota. Since the 1930s, it is known
that sorbitol can be fermented by bacteria like E. coli, Lactobacillus spp., and Streptococcus spp. [77]
which are present in our intestinal microbiota. However, so far, there has been no thorough study and
there is not enough evidence to define the specific effects of sorbitol on the gut microbiota.
2.2.7. Mannitol
Mannitol (E-421) is an isomer of sorbitol, and both are listed as hydrogenated monosaccharides.
Approximately, 75% of ingested mannitol reaches the large intestine [78]. The intestinal bacteria
metabolize D-mannitol to butyrate and propionate in animal models. Indeed, D-mannitol has been
suggested as a prebiotic, due to its stimulation of colonic butyrate and propionate production [79].
Although no data are available so far about the effects of mannitol on the gut microbiota, its role as
a substrate reflects an interaction between this polyol and the intestinal microbiota that should be
studied more deeply.
2.2.8. Xylitol
Xylitol (E-967) is a five-carbon polyol obtained from the hydrogenation of D-xylose, called wood
sugar or birch sugar. Xylitol can be directly metabolized mainly in the liver, remaining unchanged
in the gastrointestinal tract [80]. Furthermore, only a certain proportion of the ingested xylitol is
absorbed slowly from the intestinal lumen and fermented by the intestinal microbiota. Besides minor
amounts of gases such as H2, CH4, and CO2, the end products of the bacterial metabolism of xylitol
are mainly SCFA, (i.e., acetate, propionate, and butyrate). Xylitol might cause osmotic diarrhea when
the amounts consumed are too high [81]. Hence, it is expected that this polyol is capable of altering
the intestinal microbiota. Interesting results were reported, as previously mentioned, in our recent
review [1], but further studies were not reported since then.
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In summary, according to the new findings reported from February 2018, erythritol, lactitol,
and maltitol have shown to exert beneficial effects on the gut microbiota by themselves.
Nevertheless, because of the promising effect of lactitol to enhance Akkermansia proliferation in
mice with acute colitis, we encourage corroborating this finding by further studies in humans.
Overall, the latest evidence is not still enough to establish firm conclusions in relation to how polyols
influence the gut microbiota. In addition, it is necessary to highlight that some polyols could induce
laxative effects, and it would be more reliable to evaluate their effects separately. Figure 1 summarizes
the effects of different sweeteners on intestinal microbiota.
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3. Conclusions and Future Perspectives
The effects of sweeteners on gut microbiota composition are still in discussion. Even though there
are some g ps in the evidence elated to the health effects of NNS in both healt y and non-healthy
populations, authorities such as FDA, EFSA, and Codex Alimentarius consider the safe and
well-tolerated, as long as the appropriate ADI is not exceeded. Regarding NNS, neither aspartame
nor its degradation products make contact with the colonic microbiota. In contrast, though Ace-K is
absorbed and liminated by urine and almost does not contact the colonic microbiota, surprisingly,
it increases Firmicutes and depletes A. muciniphila. However, further rese rch is required in order to
firmly establish an effect in humans. We previously reported that saccharin and sucralose seem to
change the composition of the gut microbiota. However, it is necessary to take account that only 15%
of the consumed saccharin contacts the colonic microbiota, so only high doses could alter the intestinal
microbiota composition. On the contr ry, more than 85% of the consumed sucralose reaches the colon;
therefore, sucralose could potentially either alter or change the gut microbiota composition, but it is not
practically metabolized by intestinal bacteria. On the other hand, steviol glycosides directly interact
with the intestinal microbiota and need bacteria for their metabolization, so they could potentially alter
the bacterial population.
In summary, in the absence of biological plausibility, results indicating a possible alteration of
the intestinal bacteria population after the consumption of LNCS should be explained by alternative
mechanisms, suc as alterations in the ietary pattern, administration of exaggerated LNCS doses,
and co-administration of carriers.
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